No edit summary
Fix.
| drug_name =
| drug_name =
| image = 1-Naphthylmethcathinone.svg
| image = 1-Naphthylmethcathinone.svg
| image_class = skin-invert-image
| width =
| width =
| caption =
| caption =
Pharmaceutical compound
1-Naphthylmethcathinone (AMAPN) is a monoamine releasing agent of the cathinone and naphthylaminopropane families.[1][2] It is an analogue of methcathinone in which the phenyl ring has been replaced with a 1-naphthalene ring.[1][2]
The drug acts as a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA).[1][2] Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release are 21.6 nM for serotonin and 55.2 nM for dopamine, whereas the EC50 for norepinephrine was not reported.[1] However, AMAPN induced 92% release of norepinephrine at a concentration of 10,000 nM, indicating that it is an effective norepinephrine releaser as well.[1]
- ^ a b c d e
Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). “The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes”. Psychopharmacology (Berl). 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
- ^ a b c Yadav BJ (16 July 2019). Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate. VCU Scholars Compass (Thesis). doi:10.25772/MJQW-8C64. Retrieved 24 November 2024.
